Table 2.
Corticosteroid Effect in Prednisone Equivalents on Immunotherapy PFS and OS in NSCLC Studies Including at Least 50 NSCLC Patients
| Author | NSCLC (n) | Tx Type | Steroid Dose | Steroid Tx Period | % Steroid Exposure | PFS HR (Steroids: No) |
OS HR (Steroids: No) |
|---|---|---|---|---|---|---|---|
| Hendriks73 | 1025 | PD-1 | Any | 1st ICI | 14 | 1.31* CI 1.07–1.62 |
1.46* CI 1.16–1.84 |
| 255 (BM) | PD-1 | Any | 1st ICI | 27 | 2.78* CI 1.90–4.08 |
2.37* CI 1.54–3.63 |
|
| Riccuiti80 | 650 | PD-1 ± CTLA-4 | ≥ 10 mg | 1st ICI | 10 | 1.40† CI 0.89–2.00 |
1.60*† CI 1.07–2.39 |
| 0.62‡ CI 0.33–1.17 |
0.91‡ CI 0.47–1.79 |
||||||
| Arbour76 | 640 | PD-1 | ≥ 10 mg | −1 month → 1st ICI | 14 | 1.31* CI 1.03–1.67 |
1.66* CI 1.28–2.16 |
| De Giglio79 | 413 | PD-1 | ≥ 10 mg | 1st ICI → +8 weeks | 28 | 1.02¶ CI 0.51–2.02 |
1.25¶ CI 0.54–2.88 |
| 2.64*§ CI 1.24–5.61 |
4.53*§ CI 1.84–11.12 |
||||||
| Scott78 | 210 | PD-1 | > 10 mg | 1st ICI → +1 month | 31 | NA | 2.30* CI 1.27–4.16 |
| Taniguchi74 | 204 | PD-1 | Any | 1st ICI | 11 | 2.37* CI 1.44–3.74 |
2.17* CI 1.30–3.45 |
| Fuca77 | 151 | PD-1 ± CTLA-4 | ≥ 10 mg | 1st ICI → +1 month | 23 | 1.88* CI 1.08–3.28 |
2.38* CI 1.49–3.81 |
| Dumenil75 | 67 | PD-1 | Any | 1st ICI | 15 | 3.27* CI 1.39–7.69 |
1.31 CI 0.51–3.38 |
Notes: PD-1 refers to programmed death 1 or programmed death ligand 1 inhibitors. CTLA-4 refers to cytotoxic T-lymphocyte-associated protein 4 inhibitors. n refers to the patient sample size. NA indicates data not available. +Comparing steroids for cancer-related indications to no steroids. ‡Comparing steroids for cancer unrelated indications to no steroids. ¶Comparing no steroids to steroids for cancer unrelated indications. §Comparing steroids for cancer-related indications to steroids for cancer unrelated indications. *Indicates statistical significance.
Abbreviations: BM, brain metastases; Tx, treatment; HR, hazard ratio; CI, 95% confidence interval.